In recent years, the effects of various antidiabetic medications, such as SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, on diabetic MI/R injury have been extensively investigated.[39] Research on SGLT2 inhibitors primarily focuses on dapagliflozin, empagliflozin, and canagliflozin. This evidence concerns the gene GLP1R and myocardial infarction.